Mapping of Parkin mutations affecting the stability of the molecule (mutations in Zn), catalytic reactions (active site at C431), and the interactions among domains (E2-binding site) (3, 4) may help future drug development in PD and neurodegeneration by enhancing activity at the active site or by understanding further its molecular interactions. The gene discussed is PRKN; the disease is Parkinson disease.